Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics Market by Technology, Route of Administration, Application, and Region 2025-2033" has been added to ResearchAndMarkets.com's offering.
The global antisense & RNAi therapeutics market is poised for significant growth, with the market size projected to rise from USD 1.8 Billion in 2024 to USD 3.3 Billion by 2033, at a CAGR of 7.03% from 2025 to 2033. This growth is driven by a high prevalence of genetic and chronic diseases, supportive regulatory environments, and technological advancements in drug delivery systems.
Antisense & RNAi Therapeutics Market Analysis:
- Major Market Drivers: Technological advancements in drug delivery systems and the prevalence of genetic disorders and chronic diseases.
- Key Market Trends: Personalized medicine and improved patient outcomes.
- Geographical Trends: North America leads the market due to its robust healthcare infrastructure and regulatory support.
- Competitive Landscape: A dynamic market featuring traditional pharmaceutical giants and innovative newcomers battling for patents and regulatory approvals.
- Challenges and Opportunities: High development costs present both obstacles and opportunities for innovation.
Technological Advancements in Drug Delivery
Technologies that improve RNA molecule delivery have become a major driver, enhancing efficacy in targeting specific cells. Lipid nanoparticles and conjugate technologies exemplify how delivery has improved, particularly for cancer and viral infections.
Increasing Prevalence of Genetic Disorders
The growing incidence of genetic and chronic diseases propels market growth. These therapeutics represent new treatment avenues, particularly for conditions unmanageable with conventional methods, fueling investment in biopharmaceutical R&D.
Supportive Regulatory Environment
Regulatory incentives, such as orphan drug status and faster review processes, are pivotal in driving market demand. For instance, the FDA's support enhances RNAi and antisense development.
Market Segmentation
- Technology: RNA Interference, siRNA, miRNA, Antisense RNA
- Route of Administration: Includes intravenous, subcutaneous, and pulmonary delivery, with the latter holding the largest share due to its efficacy in respiratory treatments.
- Application: Oncology, cardiovascular diseases, respiratory disorders, and more.
- Region: North America leads, supported by its biotechnological infrastructure and the prevalence of target diseases.
Competitive Landscape
Key players like Alnylam Pharmaceuticals and Ionis Pharmaceuticals are increasing their R&D investments, engaging in strategic acquisitions and partnerships to harness emerging technologies. This strategy not only enhances their competitive edge but also accelerates the introduction of new RNA-based therapies to the market.
Key Questions Answered in This Report:
- Market size and expected growth rate from 2025 to 2033?
- Key factors driving market growth?
- Impact of COVID-19 on the market?
- Technology and route of administration breakdowns?
- Leading regions and key players in the market?
Key Attributes
| Report Attribute | Details |
| No. of Pages | 135 |
| Forecast Period | 2024-2033 |
| Estimated Market Value (USD) in 2024 | $1.8 Billion |
| Forecasted Market Value (USD) by 2033 | $3.3 Billion |
| Compound Annual Growth Rate | 7% |
| Regions Covered | Global |
Key Topics Covered
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Antisense & RNAi Therapeutics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Technology
- 6.1 RNA Interference
- 6.2 Antisense RNA
7 Market Breakup by Route of Administration
- 7.1 Intravenous Route
- 7.2 Subcutaneous Route
- 7.3 Intrathecal Route
- 7.4 Pulmonary Delivery
- 7.5 Intraperitoneal Injection
- 7.6 Others
8 Market Breakup by Application
- 8.1 Oncology
- 8.2 Cardiovascular Diseases (CVDs)
- 8.3 Respiratory Disorders
- 8.4 Renal Diseases
- 8.5 Neurodegenerative Disorders
- 8.6 Genetic Disorders
- 8.7 Infectious Diseases
- 8.8 Others
9 Market Breakup by Region
- 9.1 North America
- 9.2 Asia-Pacific
- 9.3 Europe
- 9.4 Latin America
- 9.5 Middle East and Africa
10 SWOT Analysis
11 Value Chain Analysis
12 Porters Five Forces Analysis
13 Price Analysis
14 Competitive Landscape
Companies Featured
- Alnylam Pharmaceuticals Inc.
- Arbutus Biopharma Corporation
- Arrowhead Pharmaceuticals Inc.
- Benitec Biopharma Ltd.
- Bio-Path Holdings Inc.
- Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
- Ionis Pharmaceuticals Inc.
- OliX Pharmaceuticals Inc.
- Phio Pharmaceuticals Corp.
- Sarepta Therapeutics Inc.
- Silence Therapeutics
- Sirnaomics Inc.
For more information about this report visit https://www.researchandmarkets.com/r/1ojq9h
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
